1. |
Kallikazaros IE.Transcatheter aortic valve replacement:current status and future prospects.Hellenic J Cardiol, 2014, 55(4):349-350.
|
2. |
Lincoln J, Garg V.Etiology of valvular heart disease.Circ J, 2014, 78(8):1801-1807.
|
3. |
van den Hanenberg F, Mairuhu G, Kalisvaart CJ, et al.Aortic valve replacement and screening for frailty.Ned Tijdschr Geneeskd, 2014, 158:A7381.
|
4. |
El-Mawardy M, Abdel-Wahab M, Richardt G.Transcatheter aortic valve implantation:technique, complications and perspectives.Expert Rev Cardiovasc Ther, 2014, 12(8):1005-1024.
|
5. |
Brinkley DM, Gelfand EV.Valvular heart disease:classic teaching and emerging paradigms.Am J Med, 2013, 126(12):1035-1042.
|
6. |
Hough A, Woods D.Antithrombotic therapy after transcatheter aortic valve replacement.JAMA, 2014, 311(12):1249-1250.
|
7. |
Steger V, Bail DH, Graf D, et al.A practical approach for bridging anticoagulation after mechanical heart valve replacement.J Heart Valve Dis, 2008, 17(3):335-342.
|
8. |
Gammie JS, Sheng S, Griffith BP, et al.Trends in mitral valve surgery in the united states:results from the society of thoracic surgeons adult cardiac surgery database.Ann Thorac Surg, 2009, 87(5):1431-1437.
|
9. |
Cerillo AG, Berti S, Glauber M.Transjugular tricuspid valve-in-valve implantation:a safe and effective approach.Ann Thorac Surg, 2011, 92(2):777-778.
|
10. |
Faerber G, Schleger S, Diab M, et al.Valve-in-valve transcatheter aortic valve implantation:the new playground for prosthesis-patient mismatch.J Interv Cardiol, 2014, 27(3):287-292.
|
11. |
Stein PD, Alpert JS, Bussey HI, et al.Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.Chest, 2001, 119(1 Suppl):220S-227S.
|
12. |
Gadey G, Reynolds MR.Cost-effectiveness considerations in transcatheter management of valvular heart disease.Can J Cardiol, 2014, 30(9):1058-1063.
|
13. |
Jategaonkar SR, Scholtz W, Horstkotte D, et al.Transfemoral aortic valve-in-valve implantation with the corevalve evolut for small degenerated stented bioprosthesis.J Invasive Cardiol, 2014, 26(6):291-294.
|
14. |
Alshehri HZ, Ismail M, Ibrahim MF.Obstructive bioprosthetic mitral valve thrombus:management options?Asian Cardiovasc Thorac Ann, 2014, 22(8):975-978.
|
15. |
Kaneko T, Cohn LH, Aranki SF.Tissue valve is the preferred option for patients aged 60 and older.Circulation, 2013, 128(12):1365-1371.
|
16. |
Suri RM, Schaff HV.Selection of aortic valve prostheses:contem-porary reappraisal of mechanical versus biologic valve substitutes.Circulation, 2013, 128(12):1372-1380.
|
17. |
von Segesser LK, Gerosa G, Borger MA, et al.Prevention and management of potential adverse events during transapical aortic valve replacement.J Heart Valve Dis, 2013, 22(3):276-286.
|
18. |
Meszaros K, Liniger S, Czerny M, et al.Mid-term results of aortic root replacement using a self-assembled biological composite graft.Interact Cardiovasc Thorac Surg, 2014, 19(4):584-589.
|
19. |
Rubino AS, Santarpino G, De Praetere H, et al.Early and interme-diate outcome after aortic valve replacement with a suturelessbio-prosthesis:results of a multicenter study.J Thorac Cardiovasc Surg, 2014, 148(3):865-871.
|
20. |
Weber A, Noureddine H, Englberger L, et al.Ten-year comparison of pericardial tissue valves versus mechanical prostheses for aortic valve replacement in patients younger than 60 years of age.J Thorac Cardiovasc Surg, 2012, 144(5):1075-1083.
|
21. |
Brown ML, Schaff HV, Lahr BD, et al.Aortic valve replacement in patients aged 50 to 70 years:improved outcome with mechanical versus biologic prostheses.J Thorac Cardiovasc Surg, 2008, 135(4):878-884.
|
22. |
Kulik A, Bedard P, Lam BK, et al.Mechanical versus bioprosthetic valve replacement in middle-aged patients.Eur J Cardiothorac Surg, 2006, 30(3):485-491.
|
23. |
Huang G, Rahimtoola SH.Prosthetic heart valve.Circulation, 2011, 123(22):2602-2605.
|
24. |
Hammermeister K, Sethi GK, Henderson WG, et al.Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve:final report of the Veterans Affairs randomized trial.J Am Coll Cardiol, 2000, 36(4):1152-1158.
|
25. |
van Geldorp MW, Eric JW, Kappetein AP, et al.Patient outcome after aortic valve replacement with a mechanical or biological prosthesis:weighing lifetime anticoagulant-related event risk against reoperation risk.J Thorac Cardiovasc Surg, 2009, 137(4):881-886.
|
26. |
Carrel TP, Englberger L.Mechanical versus bioprosthetic mitral valve replacement in patients younger than 65 years.J Thorac Cardiovasc Surg, 2014, 147(3):853-854.
|
27. |
Rahimtoola SH.Choice of prosthetic heart valve in adults an update.J Am Coll Cardiol, 2010, 55(22):2413-2426.
|
28. |
Badhwar V, Ofenloch JC, Rovin JD, et al.Noninferiority of closely monitored mechanical valves to bioprostheses overshadowed by early mortality benefit in younger patients.Ann Thorac Surg, 2012, 93(3):748-753.
|
29. |
Bach DS, Kon ND.Long-term clinical outcomes 15 years after aortic valve replacement with the Freestyle stentless aortic bioprosthesis.Ann Thorac Surg, 2014, 97(2):544-551.
|
30. |
Biglioli P, Spampinato N, Cannata A, et al.Long-term outcomes of the Carpentier-Edwards pericardial valve prosthesis in the aortic position:effect of patient age.J Heart Valve Dis, 2004, 13(Suppl 1):S49-S51.
|
31. |
Borger MA, Ivanov J, Armstrong S, et al.Twenty-year results of the HancockⅡbioprosthesis.J Heart Valve Dis, 2006, 15(1):49-56.
|
32. |
Myken PS, Bech-Hansen O.A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis.J Thorac Cardiovasc Surg, 2009, 137(1):76-81.
|
33. |
Banbury MK, Cosgrove DR, White JA, et al.Age and valve size effect on the long-term durability of the Carpentier-Edwards aortic pericardial bioprosthesis.Ann Thorac Surg, 2001, 72(3):753-757.
|
34. |
Jaquiss RD.Bioprosthetic aortic valve replacement in the young:a cautionary tale.Circulation, 2014, 130(1):7-9.
|
35. |
Dvir D, Webb JG, Bleiziffer S, et al.Transcatheter aortic valve implantation in failed bioprosthetic surgical valves.JAMA, 2014, 312(2):162-170.
|
36. |
Bonow RO, Carabello BA, Kanu C, et al.ACC/AHA 2006 guidelines for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease):developed in collaboration with the Society of Cardiovascular Anesthesiologists:endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.Circulation, 2006, 114(5):e84-e231.
|
37. |
李新民, 侯明晓, 汪曾炜, 等.老年瓣膜病患者心瓣膜置换术的临床分析.中国胸心血管外科临床杂志, 2011, 18(4):365-366.
|
38. |
袁忠祥, 杨迪成.70岁以上瓣膜病患者心瓣膜置换术235例临床分析.中国胸心血管外科临床杂志, 2011, 18(1):72-74.
|
39. |
Vahanian A, Alfieri O, Andreotti F, et al.Guidelines on the management of valvular heart disease (version 2012):the joint task force on the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).Eur J Cardiothorac Surg, 2012, 42(4):S1-S44.
|
40. |
魏大闯, 黄焕雷, 肖学钧, 等.左心瓣膜置换术后孤立性三尖瓣关闭不全的外科治疗.中国胸心血管外科临床杂志, 2014, 21(2):178-183.
|
41. |
Rescigno G, Piva T, Mazzanti I, et al.Conventional surgery results in patients originally referred for transcatheter aorticvalve implanta-tion.J Cardiovasc Med (Hagerstown), 2015, 16(4):267-270.
|
42. |
Alsara O, Alsarah A, Laird-Fick H.Advanced age and the clinical outcomes of transcatheter aortic valve implantation.J Geriatr Cardiol, 2014, 11(2):163-170.
|
43. |
Kasel AM, Cassese S, Ischinger T, et al.A prospective, non-rando-mized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis.Am J Cardiovasc Dis, 2014, 4(2):87-99.
|
44. |
Khan MS, Bawany FI, Dar MI, et al.Predictors of the size of prosthetic aortic valve and in-hospital mortality in aorticvalve replacement.Glob J Health Sci, 2014, 6(4):33877.
|
45. |
Nakamura H, Yamaguchi H, Takagaki M, et al.Rigorous patient-prosthesis matching of Perimount Magna aortic bioprosthesis.Asian Cardiovasc Thorac Ann, 2015, 23(3):261-266.
|